20170406 Telix Logo.png
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
04 oct. 2021 17h34 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
20170406 Telix Logo.png
Telix Establishes Commercial Hub in Geneva, Switzerland
04 oct. 2021 03h17 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and GENEVA, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has established a new commercial...
20170406 Telix Logo.png
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
20 sept. 2021 20h31 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the Society of Nuclear Medicine and...
20170406 Telix Logo.png
NCCN Guidelines Updated to Include PSMA-PET Imaging
13 sept. 2021 20h36 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the updated National Comprehensive Cancer...
20170406 Telix Logo.png
FDA Approves Phase II Kidney Cancer Therapy Study
13 sept. 2021 18h41 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
20170406 Telix Logo.png
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
12 sept. 2021 18h36 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Telix In-Licences Novel Tumour Microenvironment PET Tracer
09 sept. 2021 01h34 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Study Completes Enrolment
08 sept. 2021 18h57 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the last patient has been imaged in a...
20170406 Telix Logo.png
Michael Didocha Joins Telix as Chief Financial Officer, Americas
31 août 2021 07h12 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Michael Didocha has joined the...
20170406 Telix Logo.png
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
18 août 2021 18h47 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...